Management of pulmonary hypertension associated with valvular heart disease with angiotensin-receptor neprilysin inhibitor

Hyeon Ju Ryoo Ali; Jerome Thomas; Sandeep Sahay; Ashrith Guha

doi:10.1002/pul2.12303

Management of pulmonary hypertension associated with valvular heart disease with angiotensin-receptor neprilysin inhibitor

Hyeon Ju Ryoo Ali, Jerome Thomas, Sandeep Sahay, Ashrith Guha

Research output: Contribution to journal › Article › peer-review

Abstract

Pulmonary hypertension secondary to left-sided valvular disease (VHD-PH) is associated with high morbidity and mortality. Angiotensin-receptor neprilysin inhibitor (ARNI) is a novel pharmacotherapy, which reduces afterload with natriuresis and peripheral vasodilation. Our cases demonstrate that ARNI may also have a role in the treatment of combined pre- and postcapillary pulmonary hypertension that is independent of its effect on pulmonary capillary wedge pressure and cardiac output. Future prospective trials are needed to evaluate role of ARNIs in treatment of VHD-PH.

Original language	English (US)
Article number	e12303
Pages (from-to)	e12303
Journal	Pulmonary Circulation
Volume	13
Issue number	4
DOIs	https://doi.org/10.1002/pul2.12303
State	Published - Oct 2023

Keywords

cardiopulmonary pharmacology and therapeutics
congestive heart failure
hemodynamics
pulmonary hypertension

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Access to Document

10.1002/pul2.12303

Cite this

@article{acedf9bd4f2c4107bdc3a4fef71eef5f,

title = "Management of pulmonary hypertension associated with valvular heart disease with angiotensin-receptor neprilysin inhibitor",

abstract = "Pulmonary hypertension secondary to left-sided valvular disease (VHD-PH) is associated with high morbidity and mortality. Angiotensin-receptor neprilysin inhibitor (ARNI) is a novel pharmacotherapy, which reduces afterload with natriuresis and peripheral vasodilation. Our cases demonstrate that ARNI may also have a role in the treatment of combined pre- and postcapillary pulmonary hypertension that is independent of its effect on pulmonary capillary wedge pressure and cardiac output. Future prospective trials are needed to evaluate role of ARNIs in treatment of VHD-PH.",

keywords = "cardiopulmonary pharmacology and therapeutics, congestive heart failure, hemodynamics, pulmonary hypertension",

author = "Ali, {Hyeon Ju Ryoo} and Jerome Thomas and Sandeep Sahay and Ashrith Guha",

note = "Funding Information: We acknowledge the support of Dr. William Zoghbi, MD, FASE, FAHA, MACC and Dr. Stephen Chan, MD, PhD, FAHA without whom this work would not have been possible. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Publisher Copyright: {\textcopyright} 2023 The Authors. Pulmonary Circulation published by Wiley Periodicals LLC on behalf of the Pulmonary Vascular Research Institute.",

year = "2023",

month = oct,

doi = "10.1002/pul2.12303",

language = "English (US)",

volume = "13",

pages = "e12303",

journal = "Pulmonary Circulation",

issn = "2045-8932",

publisher = "SAGE Publications Inc.",

number = "4",

}

TY - JOUR

T1 - Management of pulmonary hypertension associated with valvular heart disease with angiotensin-receptor neprilysin inhibitor

AU - Ali, Hyeon Ju Ryoo

AU - Thomas, Jerome

AU - Sahay, Sandeep

AU - Guha, Ashrith

N1 - Funding Information: We acknowledge the support of Dr. William Zoghbi, MD, FASE, FAHA, MACC and Dr. Stephen Chan, MD, PhD, FAHA without whom this work would not have been possible. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Publisher Copyright: © 2023 The Authors. Pulmonary Circulation published by Wiley Periodicals LLC on behalf of the Pulmonary Vascular Research Institute.

PY - 2023/10

Y1 - 2023/10

N2 - Pulmonary hypertension secondary to left-sided valvular disease (VHD-PH) is associated with high morbidity and mortality. Angiotensin-receptor neprilysin inhibitor (ARNI) is a novel pharmacotherapy, which reduces afterload with natriuresis and peripheral vasodilation. Our cases demonstrate that ARNI may also have a role in the treatment of combined pre- and postcapillary pulmonary hypertension that is independent of its effect on pulmonary capillary wedge pressure and cardiac output. Future prospective trials are needed to evaluate role of ARNIs in treatment of VHD-PH.

AB - Pulmonary hypertension secondary to left-sided valvular disease (VHD-PH) is associated with high morbidity and mortality. Angiotensin-receptor neprilysin inhibitor (ARNI) is a novel pharmacotherapy, which reduces afterload with natriuresis and peripheral vasodilation. Our cases demonstrate that ARNI may also have a role in the treatment of combined pre- and postcapillary pulmonary hypertension that is independent of its effect on pulmonary capillary wedge pressure and cardiac output. Future prospective trials are needed to evaluate role of ARNIs in treatment of VHD-PH.

KW - cardiopulmonary pharmacology and therapeutics

KW - congestive heart failure

KW - hemodynamics

KW - pulmonary hypertension

UR - http://www.scopus.com/inward/record.url?scp=85176013695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85176013695&partnerID=8YFLogxK

U2 - 10.1002/pul2.12303

DO - 10.1002/pul2.12303

M3 - Article

C2 - 37937122

AN - SCOPUS:85176013695

SN - 2045-8932

VL - 13

SP - e12303

JO - Pulmonary Circulation

JF - Pulmonary Circulation

IS - 4

M1 - e12303

ER -

Management of pulmonary hypertension associated with valvular heart disease with angiotensin-receptor neprilysin inhibitor

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this